<DOC>
	<DOCNO>NCT02849509</DOCNO>
	<brief_summary>The aim non-interventional study describe patient 's perception anticoagulant treatment use Pradaxa® prevent stroke systemic embolism suffer atrial fibrillation ( accord approve indication approve dosage 110 mg 150 mg twice daily ) comparison standard care use Vitamin K Antagonist ( VKA ) .</brief_summary>
	<brief_title>Patient Convenience Study- NIS RELATE</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Cohort A : 1 . A . Written inform consent prior participation 2 . A . Female male patient &gt; = 18 year age diagnosis nonvalvular atrial fibrillation . 3 . A . At least 3 month continuous VKA treatment stroke prevention prior baseline assessment . 4 . A . Patients switch Pradaxa® accord Summary Product Characteristics physician ` discretion . OR Cohort B : 1 . B . Written inform consent prior participation . 2 . B . Female male patient &gt; = 18 year age newly diagnose nonvalvular atrial fibrillation previous treatment stroke prevention ( use oral anticoagulant ( OAC ) within one year prior enrolment ) . 3 . B. Stroke prevention treatment initiate Pradaxa® VKA accord Summary Product Characteristics physician ` discreton . Exclusion criterion : 1 . Contraindication use Pradaxa® VKA describe Summary Product Characteristics ( SmPC ) . 2 . Patients receive Pradaxa® VKA condition stroke prevention atrial fibrillation . 3 . Current participation clinical trial drug device . 4 . Current participation European registry use oral anticoagulation AF .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>